Sono-Tek is set to release its Q2 2027 earnings report on October 14, with analysts expecting earnings per share around $0.04-$0.05 and revenue near $5.5-$5.7 million. The company is benefiting from strong demand in the clean energy sector, recently securing $7.19 million in new orders for ultrasonic coating systems used in solar production. These orders boost Sono-Tek's backlog and provide better revenue visibility for fiscal 2028. Investors will watch the earnings report and conference call for confirmation that clean energy demand is translating into sales growth.
Sono-Tek Q2 2027 earnings preview offers context for industrial sector trends. For readers following Industrials, here is Pluang's market snapshot as of Oct 08, 2026 03:13 WIB: out of 93 US industrial stocks, 15 rose and 78 fell. Notable movers include PLUG at USD 1.78 with 12% Sell / 88% Buy order activity, RDW at USD 10.21 with 88% Sell / 12% Buy, and DE at USD 657.09 with 0% Sell / 100% Buy.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
